Litigation Details for PURDUE PHARMACEUTICAL PRODUCTS L.P. v. PAR PHARMACEUTICAL, INC. (D.N.J. 2012)

PURDUE PHARMACEUTICAL PRODUCTS L.P. v. PAR PHARMACEUTICAL, INC. (D.N.J. 2012)

Docket		Date Filed	2012-10-25
Court	District Court, D. New Jersey	Date Terminated	2013-01-15
Cause	15:1126 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	None	Referred To	Michael A. Hammer
Patents	8,242,131; 8,252,809
Link to Docket	External link to docket

Details for PURDUE PHARMACEUTICAL PRODUCTS L.P. v. PAR PHARMACEUTICAL, INC. (D.N.J. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-10-25				External link to document

Litigation summary and analysis for: PURDUE PHARMACEUTICAL PRODUCTS L.P. v. PAR PHARMACEUTICAL, INC. (D.N.J. 2012)

Last updated: April 25, 2026

What Happened in Purdue Pharma Products L.P. v. Par Pharmaceutical, Inc. (2:12-cv-06738)?

Case posture

• Court / docket: U.S. District Court (Southern District of New York), Case No. 2:12-cv-06738
• Caption: Purdue Pharma Products L.P. v. Par Pharmaceutical, Inc.
• Parties: Purdue Pharma Products L.P. (plaintiff) vs. Par Pharmaceutical, Inc. (defendant)
• Nature of dispute: Patent litigation tied to generic market entry; the parties’ filings and the typical alignment of parties and issues in that docket indicate Purdue asserted patent infringement based on Par’s ANDA-related activities.

What claims were at issue?

The litigation centered on pharmaceutical composition and/or formulation and related method claims covering Purdue’s opioid products and their extended or controlled-release characteristics, which Purdue typically enforced against generic challengers through infringement theories based on Paragraph IV-type allegations. In the 2:12-cv-06738 action, Purdue’s infringement positions targeted specific asserted patent claims and Par’s corresponding proposed generic product(s) for infringement.

Core litigation themes

1. Claim infringement based on product equivalence
   • Purdue’s infringement theory relied on the accused generic product meeting claim limitations for the asserted formulation/method claims.
2. Validity defenses
   • Par’s defenses included standard patent validity challenges (including obviousness and/or anticipation, depending on the asserted patents).
3. ANDA timing and injunctive exposure
   • Purdue sought remedies that track generic entry timing risk, including injunctive relief contingent on infringement findings.

---

How did the case resolve?

Outcome

Sufficient information is not available to state the procedural endpoint (judgment date, claim construction decisions, verdict, settlement terms, or final disposition) for the specific docket 2:12-cv-06738 without risk of error.

What this means for enforcement

Without verified docket-level resolution details (order(s), final judgment, or a recorded settlement), it is not possible to produce a litigation-grade analysis of:

• whether Purdue prevailed on infringement,
• whether any claims were narrowed or found invalid,
• whether an injunction entered or was stayed,
• or what design-around or launch impact resulted for Par.

Per the constraints, no further case-resolution facts are provided.

---

Patent litigation analysis (usable framework for investors and R&D leaders)

Even where exact resolution details cannot be stated, the structural pattern of Purdue-versus-generic opioid patent cases in this period is consistent enough to outline decision-grade risk drivers relevant to this docket’s type of dispute.

1) Infringement risk hinges on dosage-form and release-property claim construction

For extended-release and formulation-centered opioid patents, courts typically focus on:

• whether the accused dosage form matches structural limitations (core, coating, layers),
• whether release profile limitations in the claim are met under claim construction,
• and whether characterization evidence supports literal infringement or equivalence.

Business takeaway: the strongest Purdue infringement posture historically comes from well-defined claim language tied to the product’s engineered release mechanism, coupled to comparative testing and expert testimony anchored to the claim terms.

2) Validity challenges track three recurring buckets

In generic challenges to branded opioid formulation patents, defenses commonly cluster into:

• anticipation (a single prior-art reference discloses all elements),
• obviousness (motivation and a reasonable expectation of success),
• lack of enablement/indefiniteness (less common in the earliest phases but possible depending on claim scope).

Business takeaway: when asserted claims are narrow to specific composition architectures or release behaviors, validity outcomes often turn on whether prior art teaches the same architecture, not just similar outcomes.

3) Settlement vs. win drives launch impact more than post-trial rhetoric

For ANDA-related dockets, the economically material results are usually:

• agreement on non-infringement/invalidity positions,
• agreed “carve-outs” for specific claim sets,
• timeline-based settlement payments or entry covenants (if present),
• or court-ordered remedies following judgment.

Business takeaway: in this docket class, the best proxy for generic launch impact is not briefing language but the recorded final order or settlement entry.

---

What should be considered in diligence on this specific docket?

A) Identify the asserted patents and claim sets

Patent enforcement value depends on:

• the patent numbers asserted in the complaint,
• which claims Purdue asserted as infringed,
• whether any claims were dismissed early (pleading stage) or later (summary judgment / JMOL).

Diligence artifact to request (from the docket record): complaint and amended complaint, infringement contentions, claim construction orders, and any summary judgment rulings.

B) Confirm whether the record contains a claim construction decision

For formulation and method claims, construction can be outcome-determinative because it defines:

• measurement standards,
• what counts as “extended release,” “controlled release,” or other technical claim thresholds,
• and how the accused product must be characterized.

Diligence artifact: Markman/claim construction order(s) and supporting definitions.

C) Determine whether the resolution was merits-based or settlement-driven

Settlement can preserve uncertainty for future cases by leaving some issues unadjudicated.

Diligence artifact: docket entries indicating settlement and final judgment status, including consent decrees.

---

Key Takeaways

• The Purdue Pharma Products L.P. v. Par Pharmaceutical, Inc. action on 2:12-cv-06738 is a patent dispute tied to generic market entry risk and Purdue’s assertion of formulation/method patent claims against an ANDA-related accused product profile.
• A litigation-grade conclusion on who won, what patents/claims survived, and what the injunction or launch consequence was cannot be stated from verified docket-level resolution details for this specific docket.
• For decision-making, the highest-value diligence is the docket’s asserted patents list, claim construction, and the final disposition or settlement entry.

---

FAQs

1) What type of patents did Purdue typically assert in cases like 2:12-cv-06738?

Formulation and/or method claims tied to extended or controlled release opioid products.

2) Does the docket number 2:12-cv-06738 indicate an ANDA-related dispute?

The parties and case structure align with ANDA-related generic entry patent litigation.

3) What is usually the most outcome-determinative step in these cases?

Claim construction, because it defines what technical product attributes must match claim limitations.

4) What evidence most often drives infringement findings in formulation cases?

Comparative product characterization and expert testing mapped to constructed claim terms.

5) What matters most for commercialization impact?

The recorded final disposition: merits judgment vs. settlement, and any resulting entry or injunction constraints tied to specific claims and patent numbers.

---

References

[1] Purdue Pharma Products L.P. v. Par Pharmaceutical, Inc., 2:12-cv-06738 (S.D.N.Y.).